Literature DB >> 15764204

Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin.

Argyris Michalopoulos1, Sofia K Kasiakou, Evangelos S Rosmarakis, Matthew E Falagas.   

Abstract

Continuous intravenous colistin (2,000,000 units per 24 h) was administered in a 41-y-old patient with Acinetobacter baumannii bacteraemia, which led to the cure of the infection. The isolated microorganism was a multi-resistant strain (it was sensitive only to colistin). In addition, the patient had developed allergic reactions to previously administered antimicrobial agents of several classes during his hospitalization. Continuous intravenous infusion of colistin proved to be a salvage regimen, which led to cure of a bacteraemia due to a multi-resistant isolate, without showing any allergic cross-reactivity with other antibiotics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15764204     DOI: 10.1080/00365540410020776

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  15 in total

1.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Authors:  J Li; C R Rayner; R L Nation; R Deans; R Boots; N Widdecombe; A Douglas; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 5.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

6.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

7.  Colistin: the phoenix arises.

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

8.  Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.

Authors:  José María Saugar; María Jesús Rodríguez-Hernández; Beatriz G de la Torre; María Eugenia Pachón-Ibañez; María Fernández-Reyes; David Andreu; Jerónimo Pachón; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

9.  Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; Jovan Jacob; Hanna E Sidjabat; David L Paterson; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 10.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.